Edition:
India

Sage Therapeutics starts Phase 2 clinical development for SAGE-217 in movement disorders


Tuesday, 13 Dec 2016 

Sage Therapeutics Inc : Essential tremor study is anticipated to report results in second half of 2017 . Sage Therapeutics announces initiation of Phase 2 clinical development for SAGE-217 in movement disorders . Sage Therapeutics - top-line results from part a open-label study in Parkinson's disease are expected in first half of 2017 .Also plans to initiate Phase 2 clinical trials of SAGE-217 in two mood disorders.